UBS Global Biopharma Conference 2026
Logotype for Monte Rosa Therapeutic Inc

Monte Rosa Therapeutic (GLUE) UBS Global Biopharma Conference 2026 summary

Event summary combining transcript, slides, and related documents.

Logotype for Monte Rosa Therapeutic Inc

UBS Global Biopharma Conference 2026 summary

16 Nov, 2026

Molecular glue platform

  • QuEEN molecular glue degraders reshape a ubiquitin ligase surface to induce interaction with target proteins; the approach is designed to reach targets considered undruggable by other modalities.

  • VAV1 is a key example of an otherwise undruggable target being pursued with this platform.

NEK7 and cardiovascular inflammation

  • MRT-8102 degrades NEK7, an essential NLRP3 inflammasome scaffolding protein; cellular proteomics showed NEK7 degradation without other detected protein degradation across tested cell types.

  • The proposed advantages over direct NLRP3 inhibition are selective pathway shutdown and deeper, more prolonged pharmacodynamic effects, which could support safety and efficacy.

  • Management maintained conviction in upstream NLRP3 targeting after the negative ZEUS result, attributing it in part to downstream IL-6 targeting and trial-population considerations; Novartis and Roche have initiated Phase II NLRP3 inhibitor trials in ASCVD, and Novo Nordisk started a Phase I trial.

  • GFORCE-1’s four-week cohort showed calprotectin and HMGB1 returning to normal physiological levels; 5–40 mg cohorts had similar biomarker modulation.

GFORCE-2 and other 8102 indications

  • GFORCE-2 is planned to start in H1 2027, with six months of treatment in coronary artery disease; objectives include correlating fat attenuation index (FAI) with DAMPs, hsCRP and NLRP3 genetics, and assessing FAI change.

  • Management views FAI as a way to identify residual plaque inflammation; hsCRP is expected to remain useful for therapeutic response, with its predictive value dependent on targeting the right pathway node.

  • The Phase II gout study will enroll 60 patients across cohorts and assess prevention of recurrent flares after acute-flare management; readout is expected in H2 2027, with Phase III to follow if successful.

  • An HS trial is planned for H1 2027, after GFORCE-2; further preparation is underway following mixed prior trial patterns, including inverse dose responses in some Phase II studies.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Monte Rosa Therapeutic